arrow
W

Walter Elisei

a.o. s. camillo-forlanini hospital
H指数:37
被引数:4,347

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients

对经验性抗-TNF溃疡性结肠炎患者中 vedolizumab、ustekinumab 和 tofacitinib 的逆概率治疗加权比较

2026-06-150
PRE
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study

托法替布、菲洛吉替尼和乌帕替尼治疗溃疡性结肠炎的疗效和安全性比较:一项多中心真实世界队列研究

2026-05-090
OAAI
The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study

DICA内镜评分和CODA临床评分可预测急性憩室炎的严重程度及住院风险:一项国际多中心前瞻性队列研究的结果

2026-05-050
OAAI
Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

同时使用的5-氨基水杨酸不影响溃疡性结肠炎中JAK抑制剂的疗效

2026-03-050
OAAI
Therapeutic strategies for the prevention of acute diverticulitis according to the Diverticular Inflammation and Complication Assessment endoscopic score: a post hoc analysis of a prospective international study

根据Diverticular Inflammation and Complication Assessment内镜评分预防急性憩室炎的治疗策略:一项前瞻性国际研究的回顾性分析

2026-01-013
PRE
Upadacitinib’s Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study

乌帕替尼作为溃疡性结肠炎患者二线或三线治疗的有效性与安全性:真实世界研究数据

2025-11-030
OAAI
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

Tursi, A.; Mocci, G.; Costa, F.; Ceccarelli, L.; Savarino, E.; De Barba, C.; Mucherino, C.; D’antonio, E.; Montesano, L.; Marzo, M.; 等. Filgotinib 在溃疡性结肠炎患者中作为二线或三线治疗的有效性与安全性:真实世界研究数据. Intest. Res. 2025, 已接收. [CrossRef] [PubMed]

2025-09-011
PRE
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study
2025-01-300
OAAI
P0634 Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
2025-01-220
PRE
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
2025-01-220
PRE
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study
2024-11-271
OAAI
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
2024-01-256
PRE
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
2023-08-073
OAAI
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis
2023-06-147
PRE
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
2023-03-026
PRE
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

阿达木单抗生物仿制药GP2017与阿达木单抗原创者治疗炎症性肠病: 一项真实、多中心、观察性研究

2022-07-268
OAAI
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
2021-12-273
PREAI
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study
2021-05-270
PRE